# Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness

> **NCT00545142** · PHASE4 · COMPLETED · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 280 (estimated)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Abilify(Aripiprazole)
- **DRUG:** Depakote(Divalproate)

## Key facts

- **NCT ID:** NCT00545142
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2010-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00545142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00545142, "Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00545142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*